INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,328,295 | -17.7% | 25,500 | 0.0% | 0.75% | -16.0% |
| Q2 2023 | $1,614,660 | +16.9% | 25,500 | 0.0% | 0.90% | -6.0% |
| Q1 2023 | $1,380,825 | +247.9% | 25,500 | +240.0% | 0.95% | +143.1% |
| Q4 2022 | $396,900 | +166.4% | 7,500 | +87.5% | 0.39% | +931.6% |
| Q3 2021 | $149,000 | -27.0% | 4,000 | -20.0% | 0.04% | -30.9% |
| Q2 2021 | $204,000 | -14.3% | 5,000 | -28.6% | 0.06% | -31.2% |
| Q1 2021 | $238,000 | -6.3% | 7,000 | -12.5% | 0.08% | -24.5% |
| Q4 2020 | $254,000 | +1714.3% | 8,000 | +1354.5% | 0.11% | +1414.3% |
| Q3 2020 | $14,000 | – | 550 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |